Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.70 |
| ▸ | HPGD | P15428 | 7/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | CETP | P11597 | 13/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | STAT1 | P42224 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153069 | 0.85 | HPGD (0.74) | KDM4EHPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL16384057 | 0.83 | SMN1; SMN2 (0.80) | KDM4EHPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL16384045 | 0.80 | HPGD (1.00) | KDM4EHPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL1734095 | 0.78 | CETP (0.53) | KDM4EHPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL1734706 | 0.77 | CETP (1.00) | CETP | |
| SCHEMBL1733867 | 0.76 | CETP (0.73) | CETP | |
| SCHEMBL14769379 | 0.74 | HPGD (1.00) | KDM4EHPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL1734709 | 0.74 | CETP (0.69) | CETP | |
| SCHEMBL1735980 | 0.72 | CETP (0.62) | CETP | |
| SCHEMBL16151090 | 0.71 | HDAC6 (0.68) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | KDM4E 3316/4885HPGD 2024/4885SMN1; SMN2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.